Drug intelligence / Profile preview

Equazen eye q + methylphenidate

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

Equazen eye q + methylphenidate is a combination therapy consisting of the dietary supplement Equazen eye q and the pharmaceutical drug methylphenidate. - **Equazen eye q** is a nutraceutical supplement containing a specific ratio of omega-3 and omega-6 fatty acids (notably high-EPA marine fish oil, evening primrose oil, and vitamin E), designed to support brain development, concentration, focus, attention span, learning ability, working memory, reading/writing skills, and behavioral regulation in children[2][4][5][6]. - **Methylphenidate** is a central nervous system stimulant used primarily for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by modulating levels of neurotransmitters such as dopamine and norepinephrine in the brain[7]. Clinical studies have shown that combining Equazen eye q with methylphenidate may provide similar or improved efficacy compared to either agent alone for reducing ADHD symptoms in children. The combination appears to offer tolerability benefits over methylphenidate monotherapy—adverse events are less frequent when both are used together—and may improve adherence due to better side effect profiles[1][3][5][8]. The reduction in ADHD symptoms with this combination can be slower initially but tends to stabilize over time.

Brand names
Equazen eye q + methylphenidate
02

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on Equazen eye q + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equazen eye q + methylphenidate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call